Oltipraz
Canopus has confirmed in animal models:
Oltipraz as a single agent and in combination with radiation therapy, significantly reduces tumor growth
Oltipraz does not protect the tumor cells from exposure to radiation, making it an ideal candidate as an effective anti-tumor medicament.
Oltipraz was evaluated alone and in combination with the two leading chemotherapeutic agents currently on the market, cisplatin and cetuximab
Oltipraz outperformed both chemotherapy drugs individually
When combined with cisplatin and cetuximab, oltipraz enhanced the anti-tumor activity up to 90%
Canopus has initiated discussions for a Phase II trial to examine the effect of oltipraz alone and/or in combination with chemotherapy agents in cancer patients in the USA.
Cancer drug sales are now the leading therapeutic class of sales. It is estimated that sales of cancer drugs will reach $50-$75Billion by 2012. Oltipraz either alone or in combination with radiation and chemotherapy, can inhibit the growth of tumors, making it a viable candidate for use in cancer therapy.
Canopus currently has international patents pending on the use of oltipraz in the treatment and/or prevention of cancer.
CB1600
CB1600 is a substituted flavone that has demonstrated antiviral activity against certain strains of picornaviruses, notably the common cold virus (Rhinoviruses).
CB1600 and its precursors have shown antiviral activity in culture against HIV in T cells and macrophages
CB1600 has demonstrated anti-toxoplasmosis activity, in both tissue culture and animal studies comparable in activity to prescription drugs currently available for the treatment of toxoplasmosis
In the course of Canopus’ research with CB1600 it was discovered that when combined with anti-cancer or antiviral nucleotide therapeutic drugs CB1600 has the unique ability of lowering the associated toxicity of the combination drug and enhancing efficacy.
CB1600 has the unique potential to add substantial therapeutic value to current generic prescription nucleoside compounds since it synergistically lowers toxicity and, combined with its own ability to inhibit viruses and certain pathogens (toxoplasmosis), CB1600 enhances the effectiveness of the nucleoside with which it is combined. Canopus BioPharma will exploit this novel formulation advantage which CB1600 will give to generic drugs.
Canopus has a granted US patent relating to the use of CB1600 and related compounds in the treatment of infections, particularly viral or parasite infections. Additional patents are pending relating to the use of CB1600 in combination therapy for the reduction of toxicity of chemotherapeutic agents.